Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients
IRVINE, CA--(Marketwired - Sep 28, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize target medicines for target ailments. These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list.
Initial Target Ailments:
Cancers, PTSD, HIV/AIDS, Asthma, COPD, pain management, management of appetite disorders, headaches, joint and muscle pain, menstrual pain, sleep aid, seizure spectrum disorders, cold & flu, psoriasis, and others. Each study will be conducted through MD status doctor monitoring systems.
Legal self-medicating patients who wish to participate in each study are urged to submit an application early to the company to ensure their place and receive their products early. As well, the company is releasing its cancer target formulation that has had previous success in the management of certain types of cancer such as basal cell carcinoma, a common form of skin cancer. By conducting more critical ailment studies, the company moves much closer to full pharmaceutical development and commercialization.
The company website is being updated to accommodate each target ailment and once the products reach dispensary shelves, we will reach out to the many self-medicating patients looking to participate in one of the many studies. We will provide instructions on where to pick up their meds and how to attain their tracking package.
The company's new cannabis-based inhalant treatment for asthma and COPD self-medicating patients has a large interest for initial applicants. The new Natural Body & Soul Healing Balm for chronic ache and pain sufferers, the Relief Tonic for immune system bolstering, and the Solace Drops for sleep deprivation relief saw similar results in applicant interest. These products and more are on their way to select California dispensaries and study participants will receive further instructions from the company.
"Everything is coming full circle for our company. Just as we're launching our new cannabis-based medication product lines, I have been invited to speak at Harvard Medical School, which will present us with the opportunity to tell our story to highly ambitious, and talented thought leaders, while inspiring the minds of our future leaders to lead on," said Director, President, CEO & Co-Founder, Raymond C. Dabney, "Opportunities abound, and I am very excited to meet additional colleagues of like mind and spirit to help to run more effective drug development programs."
Presenting at one of the nation's most prestigious medical schools creates vast opportunity for research collaboration, cannabis-industry inspiration and expansion, and drug development as a whole. It is a huge landmark for a cannabis research and drug manufacturing company to be invited to speak at such an important academic event, and that goes to show the progress the company has made in its research and development. Additionally, Mr. Dabney's presentation opens up the floor for cannabis research discussion, innovation, and collaboration opportunities.
As these initial batches of products reach patients' hands, the company will shift its focus to expanding distribution and developing new medications to improve the lives of people suffering with other ailments.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.